Bevacizumab, one of the best-known patents of VEGF inhibitor, has demonstrated significant radiosensitive
effects on various preclinical tumor models and clinical trials recently. The radiosensitive effects of this novel patent have
achieved satisfactory efficacy through the following mechanisms: normalization of the tumor vasculature, overcoming
resistance to radiation, inhibition of repopulation after radiation, and blockade of radiation-induced increased VEGF
expression. The combination of bevacizumab with radiotherapy in the treatment of malignant tumors was an inevitable
path for the further clinical development of bevacizumab and a very good opportunity for improving the curative effect of
radiotherapy. However, many questions such as those regarding the bevacizumab administration dosage and schedule,
radio sensitivity efficacy evaluation and multi-target radiosensitive therapy need further research. The advent of bevacizumab
combined with radiation has left physicians to encounter multiple challenges as well as opportunities for improving
anti-cancer drug treatments.
Keywords: Angiogenesis, anti-angiogenic therapies, bevacizumab, radiotherapy, radiosensitivity.
promotion: free to download
Rights & PermissionsPrintExport